Ascentage Pharma Group International (ASCENTAGE-B) disclosed its monthly return for April 2026, highlighting a marginal expansion in share capital driven by option exercises.

The company’s authorised share capital stayed unchanged at 500 million ordinary shares with a par value of USD 0.0001, equivalent to USD 50,000.

Issued shares rose by 10,058 to 373,334,750, reflecting a 0.003 percent increase. No treasury shares were outstanding or transferred during the period, and the public float continued to satisfy the minimum 25 percent threshold required by the Hong Kong Stock Exchange.

Share-based incentives drove the share count change: • Pre-IPO Share Option Scheme: 10,058 options exercised, generating HKD 100.58 in proceeds and reducing outstanding options to 2,139,169. • Post-IPO Share Option Scheme: 23,638 options lapsed, leaving 609,605 outstanding and 14,194,493 shares still available for future grants. • Restricted Share Unit (RSU) Schemes: No new shares were issued; 2,160,684 shares remain available for grant under the 2022 RSU Scheme.

No warrants, convertibles, or other share-issuing instruments were reported for the month. The company confirmed that all share issuances complied with listing rules and regulatory requirements.